NZ631031A - Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor - Google Patents
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitorInfo
- Publication number
- NZ631031A NZ631031A NZ631031A NZ63103114A NZ631031A NZ 631031 A NZ631031 A NZ 631031A NZ 631031 A NZ631031 A NZ 631031A NZ 63103114 A NZ63103114 A NZ 63103114A NZ 631031 A NZ631031 A NZ 631031A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitor
- administering
- methods
- eosinophilic esophagitis
- treating eosinophilic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361844978P | 2013-07-11 | 2013-07-11 | |
| PCT/US2014/046170 WO2015006571A1 (en) | 2013-07-11 | 2014-07-10 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ631031A true NZ631031A (en) | 2017-09-29 |
Family
ID=51298948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ631031A NZ631031A (en) | 2013-07-11 | 2014-07-10 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9290574B2 (https=) |
| EP (2) | EP3659623A1 (https=) |
| JP (2) | JP6576339B2 (https=) |
| KR (2) | KR102333268B1 (https=) |
| CN (2) | CN111939261B (https=) |
| AU (2) | AU2014287196B2 (https=) |
| CA (1) | CA2917804C (https=) |
| CY (1) | CY1122909T1 (https=) |
| DK (1) | DK3019191T3 (https=) |
| ES (1) | ES2778902T3 (https=) |
| HR (1) | HRP20200628T1 (https=) |
| HU (1) | HUE049442T2 (https=) |
| IL (1) | IL279499B (https=) |
| LT (1) | LT3019191T (https=) |
| MX (2) | MX380220B (https=) |
| NZ (1) | NZ631031A (https=) |
| PL (1) | PL3019191T3 (https=) |
| PT (1) | PT3019191T (https=) |
| RS (1) | RS60151B1 (https=) |
| RU (1) | RU2679141C2 (https=) |
| SG (2) | SG10201802344YA (https=) |
| SI (1) | SI3019191T1 (https=) |
| TW (2) | TWI634900B (https=) |
| WO (1) | WO2015006571A1 (https=) |
| ZA (1) | ZA201508717B (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| NZ624922A (en) | 2009-10-01 | 2016-05-27 | Adare Pharmaceuticals Inc | Orally administered corticosteroid compositions |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| AU2016239858B2 (en) | 2015-04-02 | 2021-07-01 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| WO2017102920A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| JP2019193577A (ja) * | 2016-09-01 | 2019-11-07 | 国立研究開発法人国立成育医療研究センター | 好酸球性消化管疾患または食物蛋白誘発腸症の検査方法および検査キット |
| ES2994774T3 (en) * | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| RU2759630C2 (ru) * | 2016-09-22 | 2021-11-16 | Ридженерон Фармасьютикалз, Инк. | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| ES3052989T3 (en) | 2017-04-13 | 2026-01-16 | Regeneron Pharma | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
| EP3618872A4 (en) * | 2017-05-05 | 2021-06-30 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY STOMACH AND INTESTINAL DISEASES |
| US11053309B2 (en) * | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| IL315556A (en) * | 2017-08-04 | 2024-11-01 | Regeneron Pharma | Methods for treating active eosinophilic esophagitis |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| JP2021508719A (ja) | 2017-12-29 | 2021-03-11 | コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ | 好酸球性障害のための遺伝子療法 |
| KR102652133B1 (ko) * | 2018-02-01 | 2024-03-29 | 베이징 카윈 테크놀로지 쉐어-홀딩 컴퍼니 리미티드 | IL-4Rα 항체 및 그 용도 |
| JP2021514513A (ja) * | 2018-02-21 | 2021-06-10 | アデア ファーマシューティカルズ，ユーエス，エル．ピー． | 好酸球性食道炎を管理する方法 |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| CN113101364B (zh) | 2018-05-29 | 2023-12-01 | 康诺亚生物医药科技（成都）有限公司 | 一种自免疫抑制剂的开发和应用 |
| CN110872349A (zh) * | 2018-09-04 | 2020-03-10 | 三生国健药业（上海）股份有限公司 | 结合人il-4r的抗体、其制备方法和用途 |
| CN110746507B (zh) | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| CN116813770A (zh) * | 2018-12-27 | 2023-09-29 | 中山康方生物医药有限公司 | 抗人il-4ra的抗体及其用途 |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| WO2021011614A1 (en) | 2019-07-16 | 2021-01-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| KR20220110829A (ko) * | 2019-12-09 | 2022-08-09 | 사노피 바이오테크놀로지 | 디지털 식별된 il-4/il-13 관련 장애의 치료 방법 |
| EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
| US20230053131A1 (en) | 2019-12-20 | 2023-02-16 | Intervet Inc. | Antibodies to canine interleukin-4 receptor alpha |
| MX2022007636A (es) | 2019-12-20 | 2022-07-19 | Intervet Int Bv | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. |
| JP2023527775A (ja) * | 2020-05-22 | 2023-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 |
| AU2021359068A1 (en) | 2020-10-15 | 2023-06-15 | Intervet International B.V. | Caninized antibodies to canine interleukin-31 receptor alpha |
| WO2022099155A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN114805572B (zh) * | 2021-01-22 | 2022-12-13 | 上海济煜医药科技有限公司 | 抗原结合蛋白及其应用 |
| AU2022238849A1 (en) | 2021-03-17 | 2023-08-31 | Receptos Llc | Methods of treating atopic dermatitis with anti il-13 antibodies |
| MX2024002149A (es) | 2021-08-20 | 2024-03-08 | Intervet Int Bv | Proteinas de fusion para tratar la dermatitis atopica. |
| AU2023259287A1 (en) * | 2022-04-29 | 2024-12-12 | Akeso Biopharma, Inc | Anti-human il-4ra antibody and application thereof |
| WO2024011251A1 (en) * | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| EP4665459A1 (en) | 2023-02-13 | 2025-12-24 | Intervet International B.V. | Canine antibodies to canine il-13 |
| JP2026506599A (ja) | 2023-02-13 | 2026-02-25 | インターベット インターナショナル ベー． フェー． | イヌｉｌ－４に対するイヌ抗体 |
| IL322203A (en) * | 2023-02-17 | 2025-09-01 | Apogee Therapeutics Inc | Antibodies that bind interleukin 4 receptor alpha and methods of use |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| JPH06510750A (ja) | 1991-05-03 | 1994-12-01 | セラジェン インク | 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子 |
| JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
| US6849614B1 (en) | 1998-07-28 | 2005-02-01 | Ecosmart Technologies, Inc. | Synergistic and residual pesticidal compositions containing plant essential oils |
| WO2000016804A1 (en) | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
| EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| WO2002007745A1 (fr) | 2000-07-26 | 2002-01-31 | Yuuzou Tsuchida | Compositions antipruritiques et compositions favorisant la suberification des blessures |
| US6391531B1 (en) | 2000-11-06 | 2002-05-21 | Eastman Kodak Company | Low silver radiographic film and imaging assembly for thoracic imaging |
| WO2002051437A1 (en) | 2000-12-22 | 2002-07-04 | Societe Des Produits Nestle S.A. | Induction of tolerance |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| US20050031609A1 (en) | 2001-05-11 | 2005-02-10 | Thomas Hultsch | Compositions for use in treating ige-associated disorders |
| DK1450855T3 (da) | 2001-05-23 | 2010-01-11 | Duotol Ab | Undertrykkelse af allergiske reaktioner ved hjælp af transdermal indgivelse af allergener i forbindelse med eller konjugeret til toxin-underenheder eller fragmenter deraf |
| EP1461300B1 (en) | 2001-11-30 | 2011-07-27 | Biogen Idec MA Inc. | Antibodies against monocyte chemotactic proteins |
| ES2327830T3 (es) | 2002-03-29 | 2009-11-04 | Schering Corporation | Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen. |
| JP2006515619A (ja) * | 2003-01-07 | 2006-06-01 | チルドレンズ ホスピタル メディカル センター | 好酸球のサイトカイン阻害 |
| SI2000481T1 (sl) | 2003-02-01 | 2016-08-31 | Tanox, Inc. | Anti-humana protitelesa IgE z visoko afiniteto |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| MXPA06004853A (es) | 2003-11-07 | 2006-07-06 | Immunex Corp | Anticuerpos que se aglutinan al receptor 4 de interleucina. |
| CA2550933A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| CN1922204A (zh) * | 2004-02-27 | 2007-02-28 | 瑞泽恩制药公司 | Il－4/il－13特异性的多肽和其治疗应用 |
| AU2005219837A1 (en) | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | IL-4/IL-13 sepecific polypetides and therapeutic uses thereof |
| JP4365697B2 (ja) | 2004-03-05 | 2009-11-18 | 三菱重工業株式会社 | 印刷機の廃液再生装置及び廃液再生方法 |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US8592548B2 (en) | 2004-12-22 | 2013-11-26 | Sabic Innovative Plastics Ip B.V. | Method to prepare bis(haloimides) |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| KR100844828B1 (ko) | 2006-11-24 | 2008-07-08 | 주식회사알에프윈도우 | 안테나를 내장한 궤환 간섭신호 제거 무선중계장치 |
| PT2132230E (pt) | 2007-03-22 | 2014-07-17 | Genentech Inc | Anticorpos apoptóticos anti-ige que se ligam ao ige ligado a membrana |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| US8637239B2 (en) | 2007-11-05 | 2014-01-28 | The Board Of Trustees Of The University Of Illinois | Minimally-invasive measurement of esophageal inflammation |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| EP2376656A4 (en) | 2008-12-01 | 2012-05-16 | Cincinnati Children S Hospital Medical Ct | METHOD AND DETERMINATION OF THE EFFECTIVENESS OF A GLUCOCORTICOID TREATMENT OF EOSINOPHILIAN ESOPHAGITIS |
| WO2010120524A2 (en) | 2009-03-31 | 2010-10-21 | Altair Therapeutics, Inc. | Methods of modulating an immune response to a viral infection |
| FR2946632B1 (fr) | 2009-06-11 | 2015-05-29 | Sidel Participations | Installation de convoyage comprenant au moins un couloir courbe |
| US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
| CN102596237A (zh) | 2009-09-07 | 2012-07-18 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
| US20120164080A1 (en) | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| PH12016502073B1 (en) | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
| WO2012094643A2 (en) | 2011-01-06 | 2012-07-12 | Children's Hospital Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
| US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
| EP2723899B1 (en) | 2011-06-21 | 2020-11-18 | Children's Hospital Medical Center | Diagnostic methods for eosinophilic esophagitis |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN103974706A (zh) | 2011-10-06 | 2014-08-06 | N·V·努特里奇亚 | 嗜酸细胞性食管炎的治疗 |
| EP2790696A1 (en) * | 2011-12-16 | 2014-10-22 | Atopix Therapeutics Limited | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| KR20140119777A (ko) | 2012-01-31 | 2014-10-10 | 제넨테크, 인크. | 항-ig-e m1'' 항체 및 그의 사용 방법 |
| WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
| JP6306588B2 (ja) | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 |
| PL2892927T3 (pl) | 2012-09-07 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R |
| US10132809B2 (en) | 2012-10-10 | 2018-11-20 | Rhote Island Hospital | Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| AU2014284235C1 (en) | 2013-06-21 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods for treating nasal polyposis by administering an IL-4R antagonist |
| TWI634900B (zh) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| SG11201603127WA (en) | 2013-10-23 | 2016-05-30 | Genentech Inc | Methods of diagnosing and treating eosinophilic disorders |
| RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| KR102695088B1 (ko) | 2014-02-28 | 2024-08-16 | 리제너론 파아마슈티컬스, 인크. | Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법 |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| BR112017019412A2 (pt) | 2015-03-11 | 2018-05-02 | Glaxosmithkline Ip Dev Ltd | proteínas ligadoras de tslp |
| ES2983475T3 (es) | 2016-02-19 | 2024-10-23 | Regeneron Pharma | Métodos para mejorar la eficacia de una vacuna mediante la administración de un antagonista de IL-4R |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| TWI728172B (zh) | 2016-08-18 | 2021-05-21 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| RU2759630C2 (ru) | 2016-09-22 | 2021-11-16 | Ридженерон Фармасьютикалз, Инк. | Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3618872A4 (en) | 2017-05-05 | 2021-06-30 | Allakos Inc. | METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATORY STOMACH AND INTESTINAL DISEASES |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| RU2698048C2 (ru) | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
| KR102694419B1 (ko) | 2017-10-30 | 2024-08-09 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| JP2021514513A (ja) | 2018-02-21 | 2021-06-10 | アデア ファーマシューティカルズ，ユーエス，エル．ピー． | 好酸球性食道炎を管理する方法 |
| BR112020020387A2 (pt) | 2018-05-13 | 2021-01-19 | Regeneron Pharmaceuticals, Inc. | Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r |
| CN112261954B (zh) | 2018-06-14 | 2025-06-24 | 味之素株式会社 | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
| JP7836754B2 (ja) | 2019-08-05 | 2026-03-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法 |
| KR20220110829A (ko) | 2019-12-09 | 2022-08-09 | 사노피 바이오테크놀로지 | 디지털 식별된 il-4/il-13 관련 장애의 치료 방법 |
| IL296214A (en) | 2020-03-27 | 2022-11-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| JP2023527775A (ja) | 2020-05-22 | 2023-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 |
| US20220169739A1 (en) | 2020-10-05 | 2022-06-02 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| EP4274609A1 (en) | 2021-01-08 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist |
| WO2024011251A1 (en) | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| CN121001741A (zh) | 2023-03-27 | 2025-11-21 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法 |
-
2014
- 2014-07-09 TW TW103123563A patent/TWI634900B/zh active
- 2014-07-09 TW TW107121249A patent/TWI682781B/zh active
- 2014-07-10 RU RU2016104400A patent/RU2679141C2/ru active
- 2014-07-10 WO PCT/US2014/046170 patent/WO2015006571A1/en not_active Ceased
- 2014-07-10 AU AU2014287196A patent/AU2014287196B2/en active Active
- 2014-07-10 CA CA2917804A patent/CA2917804C/en active Active
- 2014-07-10 EP EP19217695.6A patent/EP3659623A1/en active Pending
- 2014-07-10 DK DK14748342.4T patent/DK3019191T3/da active
- 2014-07-10 KR KR1020157036466A patent/KR102333268B1/ko active Active
- 2014-07-10 PL PL14748342T patent/PL3019191T3/pl unknown
- 2014-07-10 HU HUE14748342A patent/HUE049442T2/hu unknown
- 2014-07-10 EP EP14748342.4A patent/EP3019191B1/en active Active
- 2014-07-10 LT LTEP14748342.4T patent/LT3019191T/lt unknown
- 2014-07-10 RS RS20200402A patent/RS60151B1/sr unknown
- 2014-07-10 US US14/328,336 patent/US9290574B2/en active Active
- 2014-07-10 CN CN202010829276.6A patent/CN111939261B/zh active Active
- 2014-07-10 CN CN201480038704.6A patent/CN105392497B/zh active Active
- 2014-07-10 SG SG10201802344YA patent/SG10201802344YA/en unknown
- 2014-07-10 ES ES14748342T patent/ES2778902T3/es active Active
- 2014-07-10 NZ NZ631031A patent/NZ631031A/en unknown
- 2014-07-10 JP JP2016525486A patent/JP6576339B2/ja active Active
- 2014-07-10 PT PT147483424T patent/PT3019191T/pt unknown
- 2014-07-10 KR KR1020217038483A patent/KR102398718B1/ko active Active
- 2014-07-10 SG SG11201509698SA patent/SG11201509698SA/en unknown
- 2014-07-10 HR HRP20200628TT patent/HRP20200628T1/hr unknown
- 2014-07-10 MX MX2016000271A patent/MX380220B/es unknown
- 2014-07-10 SI SI201431521T patent/SI3019191T1/sl unknown
-
2015
- 2015-11-26 ZA ZA2015/08717A patent/ZA201508717B/en unknown
-
2016
- 2016-01-08 MX MX2021002406A patent/MX2021002406A/es unknown
- 2016-02-07 US US15/017,664 patent/US10730948B2/en active Active
-
2019
- 2019-08-19 JP JP2019149548A patent/JP6837105B2/ja active Active
-
2020
- 2020-01-23 AU AU2020200497A patent/AU2020200497B2/en active Active
- 2020-05-12 CY CY20201100439T patent/CY1122909T1/el unknown
- 2020-06-24 US US16/910,884 patent/US11421036B2/en active Active
- 2020-12-16 IL IL279499A patent/IL279499B/en unknown
-
2022
- 2022-07-13 US US17/864,000 patent/US12291571B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ631031A (en) | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor | |
| AU2018253544A1 (en) | Methods for treating or preventing asthma by administering an IL-4R antagonist | |
| SG10201806787VA (en) | Modulators of complement factor b | |
| PH12015502042B1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| PH12016502062B1 (en) | Compositions and methods for modulating complement factor b expression | |
| MX365242B (es) | El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim. | |
| MX2014014970A (es) | Recordatorios de deteccion de ubicacion. | |
| MX2015010077A (es) | Terapia de combinacion para el tratamiento de neumonia nosocomial. | |
| IN2014DE01083A (https=) | ||
| MX2015008813A (es) | Composiciones y metodos para contrarrestar la inhibicion del factor xa. | |
| MX2015014344A (es) | Terapia contra el cancer. | |
| MY175326A (en) | Product and method for treating diarrhea | |
| MX2016016388A (es) | Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña. | |
| MX2017007245A (es) | Metodos de tratamiento de la fibrosis. | |
| WO2014201446A3 (en) | Use of hydrogen sulfide synthesis inhibitors for the therapy of colorectal cancers | |
| UA89489U (ru) | Способ лечения больных неалкогольным стеатогепатитом с коморбидным метаболическим синдромом | |
| UA86338U (ru) | Способ лечения беременных с гестационным диабетом | |
| IN2013MU02216A (https=) | ||
| MX2019009243A (es) | Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa. | |
| UA69464U (uk) | Спосіб лікування синдрому відміни кодтерпінової залежності у неповнолітніх | |
| UA74355U (ru) | Способ профилактики послеродового кровотечения у женщин с привычным невынашиванием беременности в анамнезе | |
| UA84204U (ru) | Способ иммунокоррекции больных ветряной оспой с наличием иммунодефицитных состояний | |
| EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы | |
| UA89983U (uk) | Спосіб профілактики ранніх та пізніх самовільних абортів у жінок із синдромом полікістозних яєчників на фоні інсулінорезистентності | |
| IN2014DE00818A (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: REGENERON PHARMACEUTICALS, INC., US Effective date: 20141023 Owner name: SANOFI, FR Effective date: 20141023 |
|
| ASS | Change of ownership |
Owner name: REGENERON PHARMACEUTICALS, INC., US Effective date: 20150730 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2019 BY ANAQUA SERVICES Effective date: 20180620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2020 BY ANAQUA SERVICES Effective date: 20190620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2021 BY ANAQUA SERVICES Effective date: 20200622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2022 BY ANAQUA SERVICES Effective date: 20210624 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2023 BY ANAQUA SERVICES Effective date: 20220621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2024 BY ANAQUA SERVICES Effective date: 20230620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2025 BY ANAQUA SERVICES Effective date: 20240619 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 JUL 2026 BY ANAQUA SERVICES Effective date: 20250620 |